Isodiol Agrees To Acquire 51% Of Round Mountain Technologies, Commences Certified Organic Hemp Farming in Nevada

CANADA: Isodiol International, a global CBD innovator specializing in hemp based health and wellness products, the development of pharmaceutical CBD delivery methods and the manufacturing of a pure, natural CBD as an Active Pharmaceutical Ingredient for use in finished pharmaceutical products, is pleased to announce that it has entered into a binding agreement to acquire 51% of Round Mountain Technologies, a cultivator of organic hemp with operations in Nevada.

RMT holds a license from the State of Nevada to cultivate organic hemp in Nye County.  The property consists of approximately 155 acres, of which RMT and Isodiol intend to plant 70 acres within the coming weeks, initially.  RMT and Isodiol will contribute to Nevada’s local economy by ensuring that all hemp harvested by RMT will be processed within the State of Nevada.

Logo-Isodiol-1500wUnder the terms of the agreement, Isodiol will commit funding of US$400,000 in cash to RMT for working capital and general obligations and issue US$250,000 in Isodiol stock based on the May 22, 2018 closing price, subject to 36-month lock-up/leak-out guidelines, in exchange for the 51% RMT ownership interest.

“This transaction is another significant milestone in Isodiol’s storied path to success,” said Marcos Agramont, CEO of Isodiol.  Mr. Agramont continued, stating, “We are pleased to be working with RMT and increasing our US organic hemp biomass supply for CBD production.”

Isodiol has successfully pursued its strategy of establishing a globally dominant position in the cultivation of jurisdictionally compliant industrial hemp and manufacturing of jurisdictionally compliant CBD consumer products.  To date, Isodiol has the ability to legally source, cultivate, and/or manufacture industrial hemp on three continents, North America, Europe, and Asia.  Additionally, Isodiol’s UK Subsidiary, BSPG Laboratories Ltd. produces CBD that has been approved as an Active Pharmaceutical Ingredient (API) by the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA) for use in Finished Pharmaceutical Products (FPPs).

“We believe we produce the purest, natural CBD in the industry.  The API is recognition of that achievement.  Isodiol will continue to pursue global recognition and approval of the API grade CBD and expand our distribution of CBD consumer products in new jurisdictions while continuing to expand our manufacturing capabilities throughout the world,” said Agramont.

“Isodiol has come to embrace the positive legal developments in legislation, regulations, and agency interpretations in jurisdictions throughout the world that have paved a legal pathway for Isodiol to legally and commercially produce pure, natural CBD from industrial hemp,” said Agramont.  Agramont went further to say, “Isodiol’s previous efforts to seek alternative sources of CBD, such as through novel hop strains, are still of interest to Isodiol, but due to favorable legislative and regulatory outcomes, Isodiol is focusing on cannabinoids produced from hemp. Presently, sources for Cannabinoids other than hemp would take longer and cost substantially more to develop.”

Isodiol To Acquire California Hemp Farm Farmtiva

CANADA:  Isodiol International Inc., a global CBD innovator specializing in the development of pharmaceutical and health and wellness products, has announced that it has entered into a binding agreement to acquire 51% of Farmtiva, a cultivator of hemp with operations in California that provides hemp farming and distribution support for farmers and other industry participants.

Farmtiva has an exclusive partnership agreement with the not-for-profit group, Imperial Valley Conservation Research Center, and together they anticipate planting the first California hemp crop within the next three weeks. This project will be a first in California for hemp legally grown under the Agricultural Act of 2014 § 7606 (“2014 Farm Bill”) in California.  As an “established agricultural research institution,” under Food and Agricultural Code (FAC) Section 81000, the project is exempt from registration and may currently grow industrial hemp in California.

California defines the rules under which hemp may be grown in Division 24 of the California Food and Agricultural Code. However, California has yet to establish a mechanism by which a farmer may grow industrial hemp pursuant to local registrations that have not yet been established. Therefore, Farmtiva and Isodiol believe they are the first group to cultivate legally grown hemp in California for more than only fiber and oil seeds.

Hemp Pioneer and Farmtiva CEO, Chris Boucher said, “This partnership enables us to operate an industrial hemp research and grow operation on the grounds of the former U.S. Department of Agriculture research facility, creating new jobs and investments in the community.” The facility consists of 160 acres, with 140 acres divided into small research plots that are leased to clients including Farmtiva. In addition to the research plots, the center houses five greenhouses and a soil testing laboratory.

This is a historical moment in California hemp history, as Boucher grew a hemp crop at the same facility in 1994 when it was operated with the USDA. “We have waited over 24 years for the laws to change and now we are very excited to move California’s agriculture hemp future forward, said Boucher.”

“Farmtiva is committed to the research and development of industrial hemp, and with the IVCRC partnership, the goal is to develop a complete industrial hemp business model whereby commercialization opportunities will be implemented to ensure use of all of the hemp by-products after CBD extraction is completed, said CEO of Isodiol, Marcos Agramont

Under the terms of this agreement, Isodiol will issue Farmtiva $1,050,000 USD in stock based on the closing price April 30th, 2018, subject to 36-month escrow guidelines, and based on Farmtiva implementing the contract rights set forth in the outstanding memorandum of understanding with IVCRC.

 

Isodiol Signs LOI To Import Cannabidiol To Canada From UK With Nuuvera

CANADA:  Isodiol and Nuuvera have agreed to import 99%+ pure, bioactive pharma-grade cannabidiol (‘CBD’) isolate into Canada from Isodiol’s GMP-certified production facility in the United Kingdom.  The product, certified as a pharmaceutical-grade, will be imported into Canada through Nuuvera’s subsidiary, ARA – Avanti Rx Analytics, a Health Canada GMP-certified laboratory holding a dealer license under the Narcotic Control Regulations and Office of Controlled Substances.

“Since establishing Isodiol, we have focused on developing and marketing the highest quality, raw material for use in a range of proprietary, pharma grade nutritional and health related remedies,” said CEO of Isodiol, Marcos Agramont.  “We are very pleased that our new partner, Nuuvera, which brings to the table extensive knowledge and expertise in the fields of quality control, cannabis extraction, purification, product development and R&D, shares Isodiol’s vision for an industry built upon quality, consistency, safety, and ultimately, efficacy.  Isodiol and Nuuvera are at the global forefront of innovation in the cannabis industry, and the ability to import to Canada is truly ground-breaking for both companies.”

Under the LOI terms, Nuuvera will import to Canada a Isodiol’s CBD isolate and conduct analytical testing in its Toronto-area laboratory to ensure that the product conforms to Isodiol’s rigorous product specifications. Nuuvera intends, ultimately, to import up to 30,000 kg of CBD isolate per month for the purposes of R&D, product formulation and production of pharma-grade derivative products.  Through its licensed subsidiaries, Nuuvera intends to then sell such products in Canada and via export to appropriately licensed international medical cannabis jurisdictions.

Level Brands And Isodiol Strike Multimillion-Dollar CBD Products Deal

NORTH CAROLINA: Level Brands has announced a licensing agreement with Vancouver-based Isodiol International to develop consumer products for kathy ireland® Health & Wellness, a licensor to Level Brands, and for Level Brands subsidiary I’M1, the company’s lifestyle brand for men.

According to a company press release, Level Brands will receive an initial US$2 million payment in the form of Isodiol shares and initial cash payments of US$62,500 due at execution of the licensing agreement and on June 30, 2018. During the term of the agreement Level will also receive US$750,000 per quarter in the form of Isodiol shares and a 3% royalty on all gross sales of branded products. The contract term is for an initial five years. Marketing materials were designed and filmed in December 2017 and both parties intend to finalize all points of the negotiations no later than January 31, 2018.

“Isodiol is an innovative, progressive and pioneering company,” says Kathy Ireland, Level Brands’ Chairman Emeritus and Chief Brand Strategist. License Global magazine names Ireland one of the 19 most influential women in the licensing industry, Ireland is the subject of multiple Forbes magazine covers, domestic and international, and Furniture Today magazine names Ireland the 18th most influential leader in the furniture industry.

“Isodiol’s success in CBD products derived from hemp are 99%+ pure, bioactive and pharmaceutical grade. The products include body balm, tincture, skincare, nano-mist and functional beverages. One of the many responsibilities in this new venture is, for me personally, to serve as Educator in Chief about cannabidiol, and how it is used by Isodiol. This company is leading the strategy of appropriate uses of hemp derivatives, and Isodiol products are free of THC. It’s ironic that people find controversy in the powerfully useful hemp plant. Without THC, hemp has many natural and important uses, which are beneficial in countless ways. We need people to please understand, that hemp, without THC, is similar to a grape without fermentation. What the Isodiol team has done is, bring the best qualities of hemp-derived CBD to the market without any psychotropic element, whatsoever. This is the second product for kathy ireland® Health & Wellness, licensed by Level Brands, and we welcome the Isodiol team to our family at Level.”

Isodiol Announces $25 Million Convertible Financing

CANADA: Isodiol, a global cannabis innovator specializing in the development of pharmaceutical and consumer products announces it has signed a convertible debenture financing for $25,000,000 CDN with Alumnia Partners.

Marcos Agramont CEO of Isodiol stated, “Our focus remains to grow revenues by developing the Isodiol brand domestically and in international markets.  This funding support allows us to further enhance our global expansion and move forward on strategic acquisitions.  Innovation and development of IP is what separates us from our competitors and we will continue to make this a priority.”

“We’re pleased to help support Isodiol’s plans to realize one of the industry’s longstanding aspirations of truly normalizing and bringing regulated cannabis into the mainstream,” added Adi Nahmani , Managing Member of Alumina Partners. “As demonstrated by their growth, Isodiol’s talented team is working diligently on many fronts to make tomorrow’s idealistic dream a commercial reality today.”

Pursuant to the terms of the offering, the debenture has no minimum draw down requirement and is a 24 month term at an annual interest rate of 8% with no upfront fees or associated costs.  Alumina Partners will commit up to $25,000,0000 CDN with conversion terms consisting of one common share (the “Shares”) and one half of one common share purchase warrant (the “Warrants”), at discounts ranging from 15% to 25% of the market price of the shares. The exercise price of the Warrants will be at a 50% premium over the market price of the Shares.